SCHEMBL4636638

SCHEMBL4636638

CCOC(=O)N1CCC(n2c(=O)[nH]c3ccc(OC)cc32)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.66
CHRM4 P08173 1/20 0.66
CHRM5 P08912 1/20 0.66
CHRM1 P11229 1/20 0.66
CHRM3 P20309 1/20 0.66
HSD11B1 P28845 4/20 0.57
OPRM1 P35372 7/20 0.56
OPRD1 P41143 4/20 0.56
OPRK1 P41145 3/20 0.56
TNKS O95271 1/20 0.56
PARP1 P09874 1/20 0.56
PARP2 Q9UGN5 1/20 0.56
HTT P42858 2/20 0.52
USP2 O75604 1/20 0.52
ALDH1A1 P00352 3/20 0.52
DRD2 P14416 1/20 0.51
DRD4 P21917 1/20 0.51
DRD3 P35462 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.50
HTR1A P08908 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006671 0.92 CHRM1 (0.65) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL2989685 0.92 CHRM1 (0.65) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL2989687 0.92 CHRM1 (0.65) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL4668824 0.88 CHRM1 (0.70) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL8857705 0.88 HTT (0.61) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL22587914 0.86 HSD11B1 (0.56) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL4635951 0.86 CHRM1 (0.67) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL4636114 0.86 CHRM1 (0.67) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL605113 0.83 CHRM1 (0.64) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL4669587 0.83 CHRM1 (0.91) CHRM2CHRM4CHRM5CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288413-B2 Benzimidazolones which have activity at M1 receptor GLAXO GROUP LIMITED (GB) 2012-10-16 US disclosed
US-8288413-B2 Benzimidazolones which have activity at M1 receptor GLAXO GROUP LIMITED (GB) 2012-10-16 US disclosed
US-8288413-B2 Benzimidazolones which have activity at M1 receptor GLAXO GROUP LIMITED (GB) 2012-10-16 US disclosed
US-20080306112-A1 Benzimidazolones Which Have Activity at M1 Receptor GLAXO GROUP LIMITED (GB) 2008-12-11 US disclosed
US-20080306112-A1 Benzimidazolones Which Have Activity at M1 Receptor GLAXO GROUP LIMITED (GB) 2008-12-11 US disclosed
US-20080306112-A1 Benzimidazolones Which Have Activity at M1 Receptor GLAXO GROUP LIMITED (GB) 2008-12-11 US disclosed
EP-1937670-A1 BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT M1 RECEPTOR GLAXO GROUP LIMITED (GB) 2008-07-02 EP disclosed
WO-2007036711-A1 BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR GLAXO GROUP LIMITED (GB) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306112-A1 Benzimidazolones Which Have Activity at M1 Receptor CHRM1, CHRM2, CHRM4 CHRM2 2/4885CHRM4 3/4885CHRM5 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.